Stimulation of antigen-presenting cells through their CD40 receptors can induce antitumor T cell responses in some murine tumor models. We have recently shown that an agonistic anti-CD40 mAb can also induce antitumor effects via activation of natural killer (NK) cells, even in the absence of T cells. Our preliminary results suggest that macrophages activated via CD40 ligation may also kill tumor cells in vivo. We also hypothesize that the T cells or NK cells activated by CD40 ligation will cause augmented antitumor destruction when combined with immunotherapeutic reagents designed to activate antitumor T cells (tumor vaccines) or NK cells (immunocytokine fusion proteins), respectively. The purpose of this project is to determine the mechanisms inducing T cell dependent or T cell independent antitumor effects in response to anti-CD40 mAb treatment, identify the specific cells and cytokines involved in these responses, and evaluate the adjuvant antitumor efficacy of anti- CD40 mAb when combined with other forms of immunotherapy. Specifically, we will accomplish this through the following 3 aims: 1. Determine the mechanisms accounting for preferential activation of T cells or NK cells in response to anti-CD40 mAb. 2. Evaluate NK cell and macrophage-mediated mechanisms of antitumor effects induced by anti-CD40 mAb. 3. Determine the role of anti-CD40 mAb in augmenting effects of immunotherapies against poorly immunogenic tumors. Together, these studies will characterize the novel, T cell-independent mechanisms of the antitumor effects induced by anti-CD40 mAb. Furthermore, they will determine how anti-CD40 mAb-activated cells may be used to further augment the antitumor effects of tumor vaccines and mAb-IL2 fusion proteins. These results may be directly implemented into the design of clinical trials potentially combining CD40 ligation with different forms of immunotherapy.
| Albertini, Mark R; Yang, Richard K; Ranheim, Erik A et al. (2018) Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunol Immunother 67:1647-1658 |
| Morris, Zachary S; Guy, Emily I; Werner, Lauryn R et al. (2018) Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites. Cancer Immunol Res 6:825-834 |
| Rakhmilevich, Alexander L; Felder, Mildred; Lever, Lauren et al. (2017) Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model. J Immunol 198:1575-1584 |
| Morris, Zachary S; Guy, Emily I; Francis, David M et al. (2016) In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. Cancer Res 76:3929-41 |
| Neri, Dario; Sondel, Paul M (2016) Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol 40:96-102 |
| Erbe, Amy K; Wang, Wei; Gallenberger, Mikayla et al. (2016) Genotyping Single Nucleotide Polymorphisms and Copy Number Variability of the FCGRs Expressed on NK Cells. Methods Mol Biol 1441:43-56 |
| Jensen, Jeffrey Lee; Rakhmilevich, Alexander; Heninger, Erika et al. (2015) Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunol Res 3:881-90 |
| McDowell, Kimberly A; Hank, Jacquelyn A; DeSantes, Kenneth B et al. (2015) NK cell-based immunotherapies in Pediatric Oncology. J Pediatr Hematol Oncol 37:79-93 |
| Shi, Yongyu; Felder, Mildred A R; Sondel, Paul M et al. (2015) Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages. Mol Immunol 66:208-15 |
| Goldberg, Jacob L; Sondel, Paul M (2015) Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Semin Oncol 42:562-72 |
Showing the most recent 10 out of 47 publications
